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Objective: Headache is the most common type of pain reported by people with schizophrenia.
This study aimed to establish prevalence, characteristics and management of these headache.
Method: One-hundred participants with schizophrenia/schizoaffective disorder completed a
reliable and valid headache questionnaire. Two clinicians independently classified each
headache as migraine (MH), tension-type (TTH), cervicogenic (CGH) or other (OH).
Results: The twelve-month prevalence of headache (57%) was higher than the general
population (46%) with no evidence of a relationship between psychiatric clinical characteristics
and presence of headache. Prevalence of CGH (5%) and MH (18%) was comparable to the
general population. TTH (16%) had a lower prevalence and 19% of participant’s experienced
OH. No-one with MH was prescribed migraine specific medication, no-one with CGH and
TTH received best-practice treatment
Conclusion: Headache is a common complaint in people with schizophrenia/schizoaffective
disorder with most fitting recognised diagnostic criteria for which effective interventions are
available. No-one in this sample was receiving best-practice care for their headache.

Despite evidence that people with schizophrenia demonstrate blunted responses to
nociception1-3, persistent pain is a common comorbidity4. Headache is the most common pain
problem reported, with 12 month prevalence of around 50%5-7. Successful management of
headache requires understanding of the mechanisms underpinning the headache experience.
To facilitate this process, the International Headache Society has published the International
Classification of Headache Disorders (ICHD) describing the important clinical features
differentiating headache disorders. To our knowledge there has been no attempt to
characterize headache types experienced by people with schizophrenia and schizoaffective
disorder and map if care provided is appropriate. The purpose of this research was to
determine prevalence, characteristics and management of common headache types
experienced by people with schizophrenia/schizoaffective disorder. This information may
help identify whether changes could be implemented to better address this manageable
physical co-morbidity amongst this population.
1.0 Methods
1.1 Ethic Statement. All participants gave written informed consent. Ethical approval
was provided through the institutional Human Research Ethics Committee. All procedures
conformed to the Declaration of Helsinki.
1.2 Study participants. One hundred adult participants with a medical diagnosis, made
by their treating psychiatrist, of schizophrenia/schizoaffective disorder were recruited from a
Metropolitan Mental Health service outpatient depot clinic and open wards between JulyNovember 2013. People attended the depot clinic for medication on a regular basis and
provided a platform to recruit community/outpatient participants. People were excluded if in
a locked ward as they did not meet selection criteria due to the acuity of their illness being

either cognitively impaired, in a critical phase of recovery which may have been destabilised
by participation in the interview process. Any person deemed by their case manager to pose a
safety risk to the interviewer was excluded.
Procedure. A previously validated headache questionnaire was identified8 and on advice
from two independent mental health practitioners the word ‘aura’ associated with MH was
replaced by the word ‘symptoms’. An algorithm was developed using ICHD criteria to
classify headache into either Cervicogenic (CGH), Tension Type (TTH) or Migraine (MH) as
well as Other Headache type (OH) when characteristics did not allow clear classification.
Pilot testing on a non-psychiatric headache population demonstrated excellent agreement
between raters when using the questionnaire and algorithm to classify headache type
(weighted-κ=0.83, 95% CI 0.65-1.00).
Potential participants were identified, approached by one of the researchers (JC) and given
detailed information regarding the project. Willing participants signed a consent form and
were enrolled into the study. Basic demographic and clinical data were collected. The
headache questionnaire was read to participants and responses recorded. Then two
researchers used the questionnaire information to independently classify each participant’s
headache against the algorithm.
1.3 Data Processing. Monthly Index of Medical Speciality (MIMS) searches were conducted
on all medication with each classified into headache as a rare/uncommon or common/very
common side effect. In every instance the highest rating of headache side effect of any of the
drugs being taken by that participant was considered.
1.4 Data Analysis. Descriptive statistics were used to report participants’ demographic,
and clinical characteristics. The twelve-month prevalence rate for headache was calculated. A
series of univariate logistic regressions were conducted to determine if age, gender, BMI,

inpatient/outpatient status, length of mental illness or medication impacted on the likelihood
of experiencing headache. Two researchers independently classified headaches. Responses
were compared and inter-rater agreement assessed using a Kappa Measure of Agreement.
Disagreements were discussed and consensus reached on classification. Overall prevalence
rates for each headache type were calculated.
Management of an individual’s headache was identified from the questionnaire and reviewed
against the best practice management suggested for that person’s specific headache type.
2.0 Results.
We consecutively screened 148 people identified by their case manager as suitable and 48
declined (Figure 1). One-hundred participants enrolled and completed the questionnaire.
Table 1 lists participants’ demographic, clinical and medication details.
The twelve-month prevalence of headache was 57% (57/100). No relationship was found
between demographic variables and presence of headache, with no significant association
between gender (OR 1.07, 95% CI 0.47-2.47, p=.87), age (OR 0.99, 95% CI 0.94-1.02, p=.25)
and BMI (OR 1.02, 95% CI 0.96-1.08, p=.58) and presence of headache. We found no
relationship between the measured psychiatric variables and presence of headache (Table 1)
with no significant association between length of time from diagnosis of mental illness and
presence of headache (OR 0.99, 95% CI 0.95-1.03, p=.61) nor inpatient/outpatient status (OR
2.07, 95% CI 0.92-4.68 p=.08). Taking medication with headache as a common/very common
side effect was not significantly related to headache status (OR 0.94, 95% CI 0.40-2.19, p=.89).
The two raters demonstrated good agreement on headache classification agreeing on 47/58
(weighted-κ=0.74, 95% CI 0.59-0.88). In all 67% (39/58) of reported headaches could be
classified as distinct headache types against ICHD diagnostic criteria with 18/58 MH, 16/58

TTH and 5/58 CGH. The prevalence of specific headache type was 17.8% (18/101) MH, 15.8%
(16/101) TTH, 4.95% (5/101) CGH and 18.8% (19/101) OH.
No participant with MH was prescribed migraine specific medication though 89% (n=16) were
taking over-the-counter pain medication. The most commonly reported treatment for TTH was
over-the-counter pain medication (75%, n=12). No-one with TTH received physical-therapy
treatment such as manual therapy, exercise, education and postural correction for management
of their headache. One participant with CGH received spinal manipulation only and none were
provided with education, exercise or other active strategies.
3.0 Discussion
The aims of this study were to determine the prevalence, characteristics and management of
headache in people with schizophrenia and schizoaffective disorder. Twelve-month prevalence
of any headache was 57%, CGH 4.9%, MH 17.8%, TTH s 15.8% and OH 18.8%. The majority
of MH (12/18) and TTH (12/16) sufferers treated themselves with over-the-counter
paracetamol and/or sleep. No-one with TTH accessed physical-therapy services. One person
with CGH received spinal manipulation but no active care.

Our data support Lake9 who argued that most headaches in this population are not a result of
psychosis, rather represent a comorbid physical illness9. We found no relationship between
presence of headache and duration of mental illness nor participants’ inpatient/outpatient
status. Furthermore, the majority of MH sufferers started experiencing MH prior to being
diagnosed with mental illness. Prevalence rates of CGH and MH in this sample were
comparable to the general population and TTH had lower prevalence10 further supporting the
idea that headache is likely separate from the psychiatric condition.

TTH (15.8%) was lower in prevalence than the general population (45%) as determined by Jull
using the same questionnaire and a similar algorithm8. It is hypothesised that TTH is the result
of pain elicited by prolonged overloading on pericranial muscles combined with sensitisation
of nociceptive pathways and abnormal pain processing in higher centres11,12. Prevalence and
intensity of responses to nociception in clinical pain is diminished in people with schizophrenia
attributed to abnormal processing of motivational-affective aspects of pain due to dysfunction
in the Inferior Prefrontal Cortex and Amygdala 2. People with schizophrenia appear to have
reduced response to prolonged nociception13. It is plausible that the sensitisation process of the
TTH experience in

the non-psychiatric population

is blunted in

people with

schizophrenia/schizoaffective disorder contributing to lower prevalence. Further investigation
is needed to investigate this hypothesis as well as determine if physical impairments driving
TTH are more severe in people with schizophrenia in order to provoke a response.
Best-practice treatment for symptoms of acute MH include administration of simple analgesics,
non-steroidal anti-inflammatory drugs and antiemetic medication14. Triptans or ergotamine
should be instigated if these measures are not effective on three occasions. To be deemed
effective treatment should provide at least 2 hours of relief15. The mean length duration of MH
was 9.8hrs (SD 20.3hrs) suggesting that the majority of MH sufferers (12/18) were not
receiving optimal care. No participant reported a neurologist review for headache nor being
prescribed triptans or ergotamine. The WHO recommend symptomatic relief should include all
symptoms, yet no-one reporting vomiting or nausea took antiemetic medication. In this survey
11/18 people (61.1%) reported MH at least monthly and 7/18 (39%) at least twice per month
suggesting their MH was insufficiently controlled and that prophylactic medication should
have been implemented.

Medication and sleep were the most common treatments adopted for TTH. Pharmacological
treatment for TTH is complex and many variables impact on which medications are the most
appropriate12. It was beyond the scope of this study to determine if participants took optimal
medication for their TTH. Neck and shoulder exercise reduce frequency and intensity of TTH
and education on ergonomics and posture can reduce the load on myofascial tissues16,17. Noone experiencing TTH reported receiving physiotherapy, exercise prescription or
ergonomics/postural review, suggesting that treatment to address headache issues was
suboptimal.
A systematic review of randomised controlled trials determined a combination of cervicalmobilisation, manipulation and cervico-scapular muscles strengthening exercises is the most
effective non-invasive management for CGH and should be the treatment of choice18. While
one participant received cervical-manipulation it has been identified that manual
therapy/manipulation without exercise prescription is a sub-standard treatment for CGH19.
Physiotherapy must be more readily available and accessible to people in this population if
they are to receive optimal treatment for headache.

The sample size calculation by a biostatistician was based on a prevalence rate for any
headache, however, it is acknowledged that a larger sample size would have provided richer
data about individual headache types. Participants were recruited from only one facility and
while their demographic data correlated to that found in a national survey of this population it
may have impacted on results. Recruiting community participants through the depot clinic
may have impacted on the data. While participants were not limited to people on a Community
Treatment Order it is unknown if the data would have been different if participants were
recruited from all outpatient services.

One potential confounder in the presence of headache is the use of the antipsychotic Olanzapine
which has been associated with reduction of headache20. The impact of Olanzapine on presence
of headache was not considered specifically in this study, however, 18.6% of people who did
not experience headache were taking Olanzapine compared to 15.8% of people who did
experience headache. It is not possible to determine if those people taking Olanzapine were
protected from headache.
The data from our survey suggests that headache is common in people with
schizophrenia/schizoaffective disorder and mechanisms behind most headaches are likely not
a direct result of their mental health condition. Overall management of headache in this
population is very poor. Very few people were receiving adequate, evidence-based treatment
for their headache. Employment of health professionals, such as physiotherapists, with skills
in headache diagnosis and management within mental health services may address this
problem.
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